HomeCompareCEVE vs ORCC

CEVE vs ORCC: Dividend Comparison 2026

CEVE yields 1000000.00% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CEVE wins by $4.7683925249533696e+36M in total portfolio value
10 years
CEVE
CEVE
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full CEVE calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — CEVE vs ORCC

📍 CEVE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCEVEORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CEVE + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CEVE pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CEVE
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, CEVE beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CEVE + ORCC for your $10,000?

CEVE: 50%ORCC: 50%
100% ORCC50/50100% CEVE
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

CEVE
No analyst data
Altman Z
-52.2
Piotroski
1/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CEVE buys
0
ORCC buys
0
No recent congressional trades found for CEVE or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCEVEORCC
Forward yield1000000.00%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$4.7683925249533696e+36M$21.4K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$1.04
Total dividends collected$4.7683311610149396e+36M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CEVE vs ORCC ($10,000, DRIP)

YearCEVE PortfolioCEVE Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,190$489.61+$100.00MCEVE
2$934,786,450,701$934,679,439,252.34$12,229$256.01+$934786.44MCEVE
3$8,165,787,108,578,292$8,164,786,887,076,042.00$13,216$130.74+$8165787108.57MCEVE
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$14,207$66.02+$66665884190957.63MCEVE
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$15,234$33.17+$508662171058048128.00MCEVE
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$16,317$16.62+$3.62723524842849e+21MCEVE
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$17,468$8.32+$2.417368115915061e+25MCEVE
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$18,695$4.16+$1.5056740286145463e+29MCEVE
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$20,006$2.08+$8.764771002818475e+32MCEVE
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$21,407$1.04+$4.7683925249533696e+36MCEVE

CEVE vs ORCC: Complete Analysis 2026

CEVEStock

Ceres Ventures, Inc., a development stage company, focuses on the research, development, and commercialization of clean technologies for the remediation of polluted water, soil, and air. Its technologies include BluFlow Nanoparticles, a proprietary system for formulating, producing, and deploying customizable absorbent nanoparticles to specific functionality for contaminant/chemical removal and extraction of valuable elements and compounds from water based solutions; BluFlow Advanced Ultrafiltration Technology, an automated process to recover water from waste or impure streams; and BluFlow Treatment System a water and wastewater treatment solution, which incorporates the BluFlow Nanoparticles and the BluFlow Advanced Ultrafiltration Technology to remove target elements, compounds, and pollutants, as well as purify water that may be suitable for reuse. Ceres Ventures, Inc.'s products are used in water and wastewater treatment and purification, contaminated groundwater treatment, industrial wastewater treatment, and valuable elements and compounds extraction applications. The company was formerly known as PhytoMedical Technologies, Inc. and changed its name to Ceres Ventures, Inc. in November 2011. Ceres Ventures, Inc. is based in New York, New York.

Full CEVE Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this CEVE vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CEVE vs SCHDCEVE vs JEPICEVE vs OCEVE vs KOCEVE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.